|
1.
|
|
20 p, 813.0 KB |
A Comprehensive Review of Ixekizumab Efficacy in Nail Psoriasis from Clinical Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis
/
Kirkham, Bruce W. (Guy's and St Thomas' NHS Foundation Trust) ;
Egeberg, Alexander (University of Copenhagen) ;
Behrens, Frank (Goethe University Frankfurt) ;
Pinter, Andreas (University Hospital Frankfurt) ;
Merola, Joseph F. (Harvard Medical School) ;
Holzkämper, Thorsten (Eli Lilly and Company) ;
Gallo, Gaia (Eli Lilly and Company) ;
Ng, Khai Jing (Eli Lilly and Company) ;
Bolce, Rebecca (Eli Lilly and Company) ;
Schuster, Christopher (Medical University of Vienna) ;
Nash, Peter (Griffith University) ;
Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ;
Universitat Autònoma de Barcelona
The online version contains supplementary material available at 10. 1007/s40744-023-00553-1.
2023 -  10.1007/s40744-023-00553-1
Rheumatology and Therapy, Vol. 10 (july 2023) , p. 1127-1146
|
|
|
2.
|
|
|
3.
|
|
16 p, 1.2 MB |
Brodalumab Versus Guselkumab in Patients with Moderate-to-Severe Psoriasis with an Inadequate Response to Ustekinumab : A Randomized, Multicenter, Double-Blind Phase 4 Trial (COBRA)
/
Reich, Kristian (University Medical Center Hamburg-Eppendorf, Hamburg, Germany) ;
Bianchi, Luca (U.O.S.D. di Dermatologia Fondazione PTV Policlinico Tor Vergata, Rome, Italy) ;
Khemis, Abdallah (Polyclinique Saint George, Groupe KANTYS, Nice, France) ;
Maul, Julia-Tatjana (University of Zürich) ;
Tsianakas, Athanasios (Fachklinik Bad Bentheim, Bad Bentheim, Germany) ;
Schempp, Christoph M. (University of Freiburg, Germany) ;
Petersen, Kim (LEO Pharma A/S, Ballerup, Denmark) ;
Noergaard, Mia M. (LEO Pharma A/S, Ballerup, Denmark) ;
Puig Sanz, Lluís (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Universitat Autònoma de Barcelona.
Departament de Medicina
Despite improved treatment options for plaque psoriasis within the last decades, some patients still have an inadequate response to treatment. Direct clinical evaluation between therapies used after biologic failure could facilitate physicians' choice of treatment. [...]
2024 - 10.1007/s13555-023-01092-x
Dermatology and Therapy, Vol. 14 (february 2024) , p. 453-468
|
|
|
4.
|
|
2 p, 292.1 KB |
Corrigendum : The paradigm of IL-23-independent production of IL-17F and IL-17A and their role in chronic inflammatory diseases(Front. Immunol., (2023), 14, (1191782), 10.3389/fimmu.2023.1191782)
/
Navarro-Compán, Victoria (Hospital Universitario La Paz (Madrid)) ;
Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ;
Vidal, Silvia (Institut d'Investigació Biomèdica Sant Pau) ;
Ramírez, Julio (Hospital Clínic i Provincial de Barcelona) ;
Llamas-Velasco, Mar (Hospital Universitario de la Princesa (Madrid)) ;
Fernández-Carballido, Cristina (Hospital Universitario San Juan de Alicante) ;
Almodóvar, Raquel (Hospital Universitario Fundación Alcorcón) ;
Pinto, José Antonio (Complejo Hospitalario Universitario de A Coruña) ;
Galíndez-Aguirregoikoa, Eva (Hospital Universitario de Basurto) ;
Zarco, Pedro (Hospital Universitario Fundación Alcorcón) ;
Joven, Beatriz (Hospital 12 de Octubre (Madrid)) ;
Gratacós, Jordi (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Juanola, Xavier (Hospital Universitari de Bellvitge) ;
Blanco, Ricardo (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria)) ;
Arias-Santiago, Salvador (Universidad de Granada) ;
Sanz Sanz, Jesús (Hospital Universitario Puerta del Hierro Majadahonda) ;
Queiro, Ruben (Hospital Universitario Central de Asturias) ;
Cañete, Juan D. (Hospital Clínic i Provincial de Barcelona) ;
Universitat Autònoma de Barcelona
In the published article, there was an error in Table 1 as published. The cell corresponding to ixekizumab in HS must be yellow rather than green, since it is not approved for that indication, nor has phase 3 clinical development been published. [...]
2023 - 10.3389/fimmu.2023.1332177
Frontiers in immunology, Vol. 14 (2023) , p. 1332177
|
|
|
5.
|
|
15 p, 3.0 MB |
Assessing the value contribution of bimekizumab for the treatment of moderate-to-severe psoriasis using a multidisciplinary reflective multi-criteria decision analysis
/
Zozaya, Néboa (Universidad de Las Palmas de Gran Canaria) ;
Abdalla, Fernando (Weber (Madrid)) ;
Alfonso Zamora, Santiago (Psoriasis and Psoriatic Arthritis Patient and Family Association) ;
Balea Filgueiras, Jesus (Complejo Hospitalario Universitario de Ferrol) ;
Carrascosa, José Manuel (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Delgado Sánchez, Olga (Hospital Universitari Son Espases (Palma de Mallorca, Balears)) ;
Dolz Sinisterra, Francisco (Hospital Universitari Doctor Peset (València)) ;
García-Ruiz, Antonio (Instituto de Investigación Biomédica de Málaga) ;
Herranz Pinto, Pedro (Hospital Universitario La Paz (Madrid)) ;
Manfredi, Antonio (Psoriasis and Psoriatic Arthritis Patient and Family Association) ;
Martínez Olmos, José (Escuela Andaluza de Salud Pública (Granada, Andalusia)) ;
Morales de Los Ríos Luna, Paloma (Hospital General Universitario Gregorio Marañón) ;
Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ;
Ros Abarca, Sandra (Institut d'Investigació Biomèdica Sant Pau) ;
Hidalgo-Vega, Álvaro (Universidad de Castilla-La Mancha) ;
Universitat Autònoma de Barcelona
Background: Multi-criteria decision analysis (MCDA) was proposed to surmount arbitrary clinical decisions in the field of biological therapies for psoriatic patients. At the same time, MCDA may further highlight the potential of bimekizumab for the treatment of moderate-to-severe psoriasis, compared to placebo, adalimumab, ustekinumab, secukinumab, and even ixekizumab and risankizumab. [...]
2022 - 10.1080/14737167.2022.2063842
Expert Review of Pharmacoeconomics and Outcomes Research, Vol. 22 Núm. 6 (2022) , p. 941-953
|
|
|
6.
|
|
|
7.
|
|
14 p, 4.2 MB |
The paradigm of IL-23-independent production of IL-17F and IL-17A and their role in chronic inflammatory diseases
/
Navarro-Compán, Victoria (Hospital Universitario La Paz (Madrid)) ;
Puig Sanz, Lluís (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Vidal, Silvia (Institut d'Investigació Biomèdica Sant Pau) ;
Ramírez, Julio (Hospital Clínic i Provincial de Barcelona) ;
Llamas-Velasco, Mar (Hospital Universitario de la Princesa (Madrid)) ;
Fernández-Carballido, Cristina (Hospital Universitario San Juan de Alicante) ;
Almodóvar, Raquel (Hospital Universitario Fundación Alcorcón) ;
Pinto, José Antonio (Complejo Hospitalario Universitario de A Coruña) ;
Galíndez-Aguirregoikoa, Eva (Hospital Universitario de Basurto) ;
Zarco, Pedro (Hospital Universitario Fundación Alcorcón) ;
Joven, Beatriz (Hospital 12 de Octubre (Madrid)) ;
Gratacós, Jordi (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Juanola, Xavier (Hospital Universitari de Bellvitge) ;
Blanco, Ricardo (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria)) ;
Arias-Santiago, Salvador (Universidad de Granada) ;
Sanz Sanz, Jesús (Hospital Universitario Puerta del Hierro Majadahonda) ;
Queiro, Ruben (Hospital Universitario Central de Asturias) ;
Cañete, Juan D. (Hospital Clínic i Provincial de Barcelona) ;
Universitat Autònoma de Barcelona
Interleukin-17 family (IL-17s) comprises six structurally related members (IL-17A to IL-17F); sequence homology is highest between IL-17A and IL-17F, displaying certain overlapping functions. In general, IL-17A and IL-17F play important roles in chronic inflammation and autoimmunity, controlling bacterial and fungal infections, and signaling mainly through activation of the nuclear factor-kappa B (NF-κB) pathway. [...]
2023 - 10.3389/fimmu.2023.1191782
Frontiers in immunology, Vol. 14 (august 2023)
|
|
|
8.
|
|
18 p, 3.4 MB |
Single-cell multi-omics analysis of COVID-19 patients with pre-existing autoimmune diseases shows aberrant immune responses to infection
/
Barmada, Anis (Department of Medical Genetics. University of Cambridge) ;
Handfield, Louis-François (Wellcome Sanger Institute (Regne Unit)) ;
Godoy-Tena, Gerard (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
de la Calle-Fabregat, Carlos (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Ciudad, Laura (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Arutyunyan, Anna (Wellcome Sanger Institute (Regne Unit)) ;
Andrés-León, Eduardo (Instituto de Parasitología y Biomedicina "López-Neyra") ;
Hoo, Regina (Wellcome Sanger Institute (Regne Unit)) ;
Porter, Tarryn (Wellcome Sanger Institute (Regne Unit)) ;
Oszlanczi, Agnes (Wellcome Sanger Institute (Regne Unit)) ;
Richardson, Laura (Wellcome Sanger Institute (Regne Unit)) ;
Calero-Nieto, Fernando (Department of Haematology and Wellcome & MRC Cambridge Stem Cell Institute. University of Cambridge) ;
Wilson, Nicola K. (Department of Haematology and Wellcome & MRC Cambridge Stem Cell Institute. University of Cambridge) ;
Marchese, Domenica (Centre de Regulació Genòmica) ;
Sancho-Serra, Carmen (Wellcome Sanger Institute. Wellcome Genome Campus) ;
Carrillo, Jorge (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ;
Presas-Rodríguez, Silvia (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Ramo-Tello, Cristina (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Ruiz-Sanmartin, Adolfo (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Ferrer, Ricard (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Ruiz-Rodriguez, Juan Carlos (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Martínez Gallo, Mónica (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Munera-Campos, Mónica (Institut Germans Trias i Pujol) ;
Carrascosa, José Manuel (Institut Germans Trias i Pujol) ;
Göttgens, Berthold (Department of Haematology and Wellcome & MRC Cambridge Stem Cell Institute. University of Cambridge) ;
Heyn, Holger (Universitat Pompeu Fabra) ;
Prigmore, Elena (Wellcome Sanger Institute (Regne Unit)) ;
Casafont-Solé, Ivette (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Solanich, Xavier (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Sánchez-Cerrillo, Idelfonso (Department of Immunology. Hospital Universitario La Princesa) ;
González-Álvaro, Isidoro (Rheumatology Service. Hospital Universitario La Princesa) ;
Raimondo, Maria Gabriella (Deutsches Zentrum Immuntherapie. Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen) ;
Ramming, Andreas (Deutsches Zentrum Immuntherapie. Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen) ;
Martin, Javier (Instituto de Parasitología y Biomedicina "López-Neyra") ;
Martínez Cáceres, Eva María (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
Ballestar, Esteban (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Vento-Tormo1, Roser (Wellcome Sanger Institute. Wellcome Genome Campus) ;
Rodríguez-Ubreva, Javier (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
In COVID-19, hyperinflammatory and dysregulated immune responses contribute to severity. Patients with pre-existing autoimmune conditions can therefore be at increased risk of severe COVID-19 and/or associated sequelae, yet SARS-CoV-2 infection in this group has been little studied. [...]
2024 - 10.1002/eji.202350633
European Journal of Immunology, Vol. 54 Núm. 1 (january 2024) , p. 2350633
|
|
|
9.
|
|
5 p, 414.7 KB |
Long-term impact of ixekizumab on psoriasis itch severity : Results from a phase III clinical trial and long-term extension
/
Kimball, Alexandra B. (Harvard Medical School) ;
Luger, Thomas (University of Muenster) ;
Gottlieb, Alice (New York Medical College) ;
Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ;
Kaufmann, Roland (Goethe University) ;
Burge, Russel (University of Cincinnati) ;
Lin, Chen-Yen (Eli Lilly and Company) ;
Yosipovitch, Gil (University of Miami Miller School Of Medicine) ;
Universitat Autònoma de Barcelona
Itching is a prevalent plaque psoriasis symptom. Ixekizumab, an IL-17A antagonist, has demonstrated rapid, significant improvements in itch severity over 12 weeks in Phase III psoriasis trials (UNCOVER-1, UNCOVER-2). [...]
2018 - 10.2340/00015555-2801
Acta dermato-venereologica, Vol. 98 Núm. 1 (2018) , p. 98-102
|
|
|
10.
|
|
6 p, 377.9 KB |
Clinical and genetic differences between pustular psoriasis subtypes
/
Twelves, Sophie (King's College London) ;
Mostafa, Alshimaa (Beni Suef University) ;
Dand, Nick (King's College London) ;
Burri, Elias (University Hospital Zurich (Suïssa)) ;
Farkas, K. (University of Szeged) ;
Wilson, Rosemary (King's College London) ;
Cooper, Hywel L. (Portsmouth Hospitals Trust) ;
Irvine, Alan D. (Trinity College Dublin) ;
Oon, Hazel H. (National Skin Centre) ;
Kingo, Külli (Tartu University Hospital (Tartu, Estònia)) ;
Köks, Sulev (University of Tartu) ;
Mrowietz, Ulrich (University Medical Center Schleswig-Holstein) ;
Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ;
Reynolds, Nick (Newcastle Hospitals NHS Foundation Trust) ;
Tan, Euegene Sern-Ting (National Skin Centre) ;
Tanew, Adrian (Medical University of Vienna) ;
Torz, Kaspar (Campus Kiel) ;
Trattner, Hannes (Medical University of Vienna) ;
Valentine, Mark (University of Washington School of Medicine) ;
Wahie, Shyamal (University Hospital of North Durham and Darlington Memorial Hospital) ;
Warren, Richard B. (University of Manchester and the Academic Health Science Centre) ;
Wright, Andrew (St University of Bradford) ;
Bata-Csörgő, Zsuzsa (University of Szeged) ;
Szell, Marta (University of Szeged) ;
Griffiths, Christopher E.M. (University of Manchester and the Academic Health Science Centre) ;
Burden, A.David (University of Glasgow) ;
Choon, Siew-Eng (Monash University Malaysia) ;
Smith, Catherine H. (King's College London) ;
Barker, Jonathan N. (King's College London) ;
Navarini, Alexander A. (University Hospital Zurich (Suïssa)) ;
Capon, Francesca (King's College London) ;
Universitat Autònoma de Barcelona
The term pustular psoriasis indicates a group of severe skin disorders characterized by eruptions of neutrophil-filled pustules. The disease, which often manifests with concurrent psoriasis vulgaris, can have an acute systemic (generalized pustular psoriasis [GPP]) or chronic localized (palmoplantar pustulosis [PPP] and acrodermatitis continua of Hallopeau [ACH]) presentation. [...]
2019 - 10.1016/j.jaci.2018.06.038
The Journal of Allergy and Clinical Immunology, Vol. 143 Núm. 3 (march 2019) , p. 1021-1026
|
|
visitant ::
identificació
alerta personal via correu electrònic o subscribiu-vos al 
canal RSS.
